Navigation Links
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Date:9/7/2007

SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three clinical data abstracts about its oral chemotherapy treatment Xeloda have been accepted for presentation at the 2007 Breast Cancer Symposium in San Francisco, Sept. 7 and 8.

Two of the abstracts include data from the XeNA (Xeloda in NeoAdjuvant) trial, a study of Xeloda and docetaxel with or without Herceptin in patients with invasive breast cancer. The third presentation highlights findings that validate efficacy and cost benefits of Xeloda in breast cancer patients.

-- Poster No. A54, [General Poster Session A, Sept. 7, 12:00 - 12:45

p.m.], "Frequency of circulating tumor cells (CTCs) in an open-label

study of neoadjuvant capecitabine, docetaxel and trastuzumab (CDT)

combination therapy in patients with HER2+ breast cancer (BC)."

(Presenter: Stefan Gluck)

-- Poster No. 100, [General Poster Session C, Sept. 8, 7:00 - 8:00 a.m.],

"Distribution of p53 mutations by AmpliChip assay in patients receiving

neoadjuvant capecitabine (C) plus docetaxel (D) with or without

trastuzumab (T) for newly diagnosed breast cancer (BC)." (Presenter:

Nancy Patten)

-- Poster No. A41, [General Poster Session D, Sept. 8, 11:45 a.m. - 12:45

p.m.], "Capecitabine is associated with fewer adverse events than other

standard therapies in patients with breast cancer: a claims database

analysis." (Presenter: Hope Rugo, M.D.)

These studies affirm Roche's commitment to exploring the expanded use of Xeloda in combination with new therapies. Additionally, the data explore the potential of oral Xeloda to offer effective treatment with a lower incidence of adverse events compared with traditional intravenous chemotherapy.

About Xeloda

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill for
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014  AbbVie (NYSE: ... studies evaluating potential new medicines in the company,s ... 2014 European Society of Medical Oncology (ESMO) Annual ... . Data being presented include results from ... efficacy of veliparib (ABT-888), a poly (adenosine diphosphate ...
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... NEW YORK , Sept. 22, ... has signed an exclusive, global license agreement with ... commercialization of its proprietary plasma fractionation process. Concurrently, ... and its intention to strategically refocus and rebrand ... plans to pursue a national listing for its ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) today reported ... Cash, cash equivalents, and investments at September 30, ... 31, 2010. Revenue for the third quarter of ... in the third quarter of 2010 primarily as a result of ...
... NEW YORK, Nov. 2, 2011 JDRF and The Leona ... largest non-government funders of type 1 diabetes (T1D) programs, announced ... a new level of cooperation between the organizations. The goal ... and development to deliver better treatments, devices, and diagnostics for ...
Cached Medicine Technology:Nektar Therapeutics Reports Third Quarter 2011 Financial Results 2Nektar Therapeutics Reports Third Quarter 2011 Financial Results 3Nektar Therapeutics Reports Third Quarter 2011 Financial Results 4Nektar Therapeutics Reports Third Quarter 2011 Financial Results 5Nektar Therapeutics Reports Third Quarter 2011 Financial Results 6Nektar Therapeutics Reports Third Quarter 2011 Financial Results 7Nektar Therapeutics Reports Third Quarter 2011 Financial Results 8JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 2JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 3JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 4
(Date:9/22/2014)... Severe weather can occur with little warning, so it’s ... of National Preparedness Month, Amica Insurance is offering the ... unexpected:, , Build an emergency supply kit. It ... gallon of water per person per day for at least 72 ... includes pets so your family knows what to do and where ...
(Date:9/22/2014)... County, NY (PRWEB) September 22, 2014 ... joined the Department of Surgery at the Icahn School ... Sinai Doctors New York Group for Plastic Surgery gives ... Valley access to a team of world-renowned plastic surgeons ... Additionally, C. Andrew Salzberg, MD, who led NYGPS, was ...
(Date:9/22/2014)... -- Metformin, a drug commonly used to treat diabetes, ... hormone (TSH) among patients with an underactive thyroid, a ... TSH levels may be associated with heart problems and ... in this study. Among those in the study ... of low levels of thyroid-stimulating hormone per year compared ...
(Date:9/22/2014)... 22, 2014 The report segments ... end user, and geography. The equipment segment accounted ... equipment market, by product. However, the accessories segment ... in the forecast period, owing to the rising ... stimulation and ultrasound segments are the fastest-growing segments ...
(Date:9/22/2014)... step for securing critical information systems, such as ... have created a new approach to computer security ... a terminal and automatically logs them out when ... to use their terminal. , Dartmouth,s Trustworthy ... their findings at the IEEE Symposium ...
Breaking Medicine News(10 mins):Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3
... 5.6 Onboard Software to Navigate the Safest, Most Fuel-Efficient Route and Protect ... the World,s Poor , ... Sunnyvale, Calif. (Vocus) March 16, 2009 -- ... , the leader in using hospital ships to deliver free, world-class health ...
... making great money is a reality. This year we focus on advancing ... Social Engineering. Spring ChicagoCon 2009 by TDCC features world-class security training followed ... career on the cutting edge of technology and the human mind. ... ...
... harm that often follows brain injury, researcher says, , , ... of Alzheimer,s disease drugs may prevent long-term damage from ... Georgetown University Medical Center researchers. , The drugs -- ... that accumulates in the brains of people with Alzheimer,s ...
... getaway destinations are affected, studies find , , SUNDAY, March 15 ... can be a burden on a family,s finances and even ... be presented in Washington, D.C., at the annual meeting of ... these common conditions can have a wide impact on a ...
... All-In-One Mobility Solutions , ... Blue ... proud to announce the branding of RACO,s Advanced Solutions Group ... area network design, RFID compliance and application software development services ...
... WILMINGTON, Del., March 14 Today AstraZeneca ... in response to the appointment of a new FDA ... Commissioner of the Food and Drug Administration. Dr. Hamburg ... will serve the agency well in these challenging times. ...
Cached Medicine News:Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 2Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 3Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 4Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 5Health News:Chicago's Own Hacker Con Set for May, Teaches Human Hacking to Corporations 2Health News:Chicago's Own Hacker Con Set for May, Teaches Human Hacking to Corporations 3Health News:Alzheimer's Drug May Someday Help Head Trauma Victims 2Health News:Child's Food Allergies Take Toll on Family Plans 2Health News:RACO Brands Its Advanced Solutions Group 2Health News:AstraZeneca Applauds Appointment of New FDA Commissioner 2
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
Medicine Products: